SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - Soleno Therapeutics, Inc. is facing a class action lawsuit for securities fraud due to misleading statements regarding the safety and commercial viability of its DCCR treatment [1] Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Soleno Therapeutics for violations of the Securities Exchange Act of 1934 [1] - Investors who purchased Soleno's securities between March 26, 2025, and November 4, 2025, are encouraged to participate in the lawsuit before May 5, 2026 [1] - The lawsuit claims that Soleno made false and misleading statements about the safety concerns of its DCCR treatment revealed in a Phase 3 clinical trial [1] Group 2: Allegations Against Soleno - The company allegedly downplayed safety risks associated with its DCCR treatment, which had greater risks than disclosed [1] - The DCCR treatment was reported to have lower commercial viability and a heightened risk of adverse events [1] - Public statements made by Soleno were deemed false and materially misleading throughout the class period [1]